Sanaa M Kamal

Summary

Country: USA

Publications

  1. doi Hepatitis C genotype 4 therapy: increasing options and improving outcomes
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Liver Int 29:39-48. 2009
  2. doi Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis
    Sanaa M Kamal
    Department of Hepatology, Infectious Diseases and Tropical Medicine, Ain Shams Faculty of Medicine, University of Ain Shams, Cairo, Egypt
    Liver Int 31:401-11. 2011
  3. doi Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study
    Sanaa M Kamal
    Department of Infectious Diseases, Gastroenterology and Tropical Medicine, Ain Shams Faculty of Medicine, Cairo, Egypt
    Am J Gastroenterol 109:199-211. 2014
  4. doi Hepatitis C virus genotype 4 therapy: progress and challenges
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Liver Int 31:45-52. 2011
  5. ncbi Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
    Sanaa M Kamal
    Department of Gastroenterology and Hepatology, Ain Shams University, Cairo, Egypt
    Hepatology 46:1732-40. 2007
  6. doi Hepatitis C genotype 4: What we know and what we don't yet know
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Hepatology 47:1371-83. 2008
  7. doi Acute hepatitis C: a systematic review
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Am J Gastroenterol 103:1283-97; quiz 1298. 2008
  8. pmc Viral hepatitis a to e in South mediterranean countries
    Sanaa M Kamal
    Department of Tropical Medicine, Gastroenterology and Liver Disease, Ain Shams University, Cairo, Egypt
    Mediterr J Hematol Infect Dis 2:e2010001. 2010

Collaborators

Detail Information

Publications8

  1. doi Hepatitis C genotype 4 therapy: increasing options and improving outcomes
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Liver Int 29:39-48. 2009
    ..Rapid and early virological responses have been useful tools for determination of the duration of therapy...
  2. doi Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis
    Sanaa M Kamal
    Department of Hepatology, Infectious Diseases and Tropical Medicine, Ain Shams Faculty of Medicine, University of Ain Shams, Cairo, Egypt
    Liver Int 31:401-11. 2011
    ....
  3. doi Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study
    Sanaa M Kamal
    Department of Infectious Diseases, Gastroenterology and Tropical Medicine, Ain Shams Faculty of Medicine, Cairo, Egypt
    Am J Gastroenterol 109:199-211. 2014
    ..The objective of this study was to characterize the factors that influence the outcome of exposure to hepatitis C virus (HCV) genotype 4 (HCV-G4) and the course of recent infection...
  4. doi Hepatitis C virus genotype 4 therapy: progress and challenges
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Liver Int 31:45-52. 2011
    ....
  5. ncbi Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
    Sanaa M Kamal
    Department of Gastroenterology and Hepatology, Ain Shams University, Cairo, Egypt
    Hepatology 46:1732-40. 2007
    ..001) were also associated with SVR attainment. The incidence of adverse events and the rate of discontinuation were higher in patients in the variable-duration and fixed-duration groups treated for 48 weeks...
  6. doi Hepatitis C genotype 4: What we know and what we don't yet know
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Hepatology 47:1371-83. 2008
    ..These data can now be used as a platform for further research to define optimal treatment duration and predictors of SVR in patients with HCV-4 infection...
  7. doi Acute hepatitis C: a systematic review
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Am J Gastroenterol 103:1283-97; quiz 1298. 2008
    ..We scanned the literature for predictors of spontaneous resolution and treatment during the acute stage of HCV to identify factors that would assist in treatment decision making...
  8. pmc Viral hepatitis a to e in South mediterranean countries
    Sanaa M Kamal
    Department of Tropical Medicine, Gastroenterology and Liver Disease, Ain Shams University, Cairo, Egypt
    Mediterr J Hematol Infect Dis 2:e2010001. 2010
    ....